 BLACKSBURG, Va., Aug. 26, 2021 GLOBE NEWSWIRE -- Landos Biopharma, Inc. NASDAQ: LABP, a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that it has entered into a research collaboration with Peter Calabresi, M.D., Director of the Multiple Sclerosis Center and Professor of Neurology at Johns Hopkins University JHU School of Medicine. This research funded by the National Institutes of Health NIH will focus on further validating the NLRX1 immunometabolic pathway in Multiple Sclerosis MS. 